Structural Basis of the Activation of the CC Chemokine Receptor 5 by a Chemokine Agonist
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin Michelle L
CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin Michelle L. McCully, Kristin Ladell, Robert Andrews, Rhiannon E. Jones, Kelly L. Miners, Laureline Roger, This information is current as Duncan M. Baird, Mark J. Cameron, Zita M. Jessop, Iain S. of September 24, 2021. Whitaker, Eleri L. Davies, David A. Price and Bernhard Moser J Immunol published online 2 February 2018 http://www.jimmunol.org/content/early/2018/02/02/jimmun Downloaded from ol.1701377 Supplementary http://www.jimmunol.org/content/suppl/2018/02/02/jimmunol.170137 Material 7.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 The Authors All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 2, 2018, doi:10.4049/jimmunol.1701377 The Journal of Immunology CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin Michelle L. -
G Protein-Coupled Receptors As Therapeutic Targets for Multiple Sclerosis
npg GPCRs as therapeutic targets for MS Cell Research (2012) 22:1108-1128. 1108 © 2012 IBCB, SIBS, CAS All rights reserved 1001-0602/12 $ 32.00 npg REVIEW www.nature.com/cr G protein-coupled receptors as therapeutic targets for multiple sclerosis Changsheng Du1, Xin Xie1, 2 1Laboratory of Receptor-Based BioMedicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sci- ences and Technology, Tongji University, Shanghai 200092, China; 2State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guo Shou Jing Road, Pudong New District, Shanghai 201203, China G protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmit- ters and environmental stimulants. They are considered as the most successful therapeutic targets for a broad spec- trum of diseases. Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated de- myelination and degeneration of the central nervous system (CNS). It is the leading cause of non-traumatic disability in young adults. Great progress has been made over the past few decades in understanding the pathogenesis of MS. Numerous data from animal and clinical studies indicate that many GPCRs are critically involved in various aspects of MS pathogenesis, including antigen presentation, cytokine production, T-cell differentiation, T-cell proliferation, T-cell invasion, etc. In this review, we summarize the recent findings regarding the expression or functional changes of GPCRs in MS patients or animal models, and the influences of GPCRs on disease severity upon genetic or phar- macological manipulations. -
Th2 Effector Lymphocytes Regulatory and + Cells Enriched for FOXP3
CCR8 Expression Identifies CD4 Memory T Cells Enriched for FOXP3 + Regulatory and Th2 Effector Lymphocytes This information is current as Dulce Soler, Tobias R. Chapman, Louis R. Poisson, Lin of September 27, 2021. Wang, Javier Cote-Sierra, Mark Ryan, Alice McDonald, Sunita Badola, Eric Fedyk, Anthony J. Coyle, Martin R. Hodge and Roland Kolbeck J Immunol 2006; 177:6940-6951; ; doi: 10.4049/jimmunol.177.10.6940 Downloaded from http://www.jimmunol.org/content/177/10/6940 References This article cites 68 articles, 27 of which you can access for free at: http://www.jimmunol.org/content/177/10/6940.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CCR8 Expression Identifies CD4 Memory T Cells Enriched for FOXP3؉ Regulatory and Th2 Effector Lymphocytes Dulce Soler,1 Tobias R. -
Temporal Expression and Cellular Origin of CC Chemokine Receptors
Journal of Neuroinflammation BioMed Central Research Open Access Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE Sana Eltayeb1, Anna-Lena Berg*2, Hans Lassmann3, Erik Wallström1, Maria Nilsson4, Tomas Olsson1, Anders Ericsson-Dahlstrand4 and Dan Sunnemark4 Address: 1Department of Clinical Neuroscience, Center for Molecular Medicine, Neuroimmunology Unit, Karolinska Institute, S-171 76 Stockholm, Sweden, 2Department of Pathology, Safety Assessment, AstraZeneca R&D Södertälje, S-15185 Södertälje, Sweden, 3Brain Research Institute, University of Vienna, Vienna, Austria and 4Department of Disease Biology, Local Discovery Research Area CNS and Pain Control, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden Email: Sana Eltayeb - [email protected]; Anna-Lena Berg* - [email protected]; Hans Lassmann - [email protected]; Erik Wallström - [email protected]; Maria Nilsson - [email protected]; Tomas Olsson - [email protected]; Anders Ericsson-Dahlstrand - [email protected]; Dan Sunnemark - [email protected] * Corresponding author Published: 7 May 2007 Received: 5 February 2007 Accepted: 7 May 2007 Journal of Neuroinflammation 2007, 4:14 doi:10.1186/1742-2094-4-14 This article is available from: http://www.jneuroinflammation.com/content/4/1/14 © 2007 Eltayeb et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The CC chemokine receptors CCR1, CCR2 and CCR5 are critical for the recruitment of mononuclear phagocytes to the central nervous system (CNS) in multiple sclerosis (MS) and other neuroinflammatory diseases. -
Use of Alternate Coreceptors on Primary Cells by Two HIV-1 Isolates
Edinburgh Research Explorer Use of alternate coreceptors on primary cells by two HIV-1 isolates Citation for published version: Cilliers, T, Willey, S, Sullivan, WM, Patience, T, Pugach, P, Coetzer, M, Papathanasopoulos, M, Moore, JP, Trkola, A, Clapham, P & Morris, L 2005, 'Use of alternate coreceptors on primary cells by two HIV-1 isolates', Virology, vol. 339, no. 1, pp. 136-44. https://doi.org/10.1016/j.virol.2005.05.027 Digital Object Identifier (DOI): 10.1016/j.virol.2005.05.027 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Virology Publisher Rights Statement: Copyright 2005 Elsevier Inc. General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 Virology 339 (2005) 136 – 144 www.elsevier.com/locate/yviro Use of alternate coreceptors on primary cells by two HIV-1 isolates Tonie Cilliersa, Samantha Willeyb, W. Mathew Sullivanb, Trudy Patiencea, Pavel Pugachc, Mia Coetzera, Maria Papathanasopoulosa,1, John P. -
Part One Fundamentals of Chemokines and Chemokine Receptors
Part One Fundamentals of Chemokines and Chemokine Receptors Chemokine Receptors as Drug Targets. Edited by Martine J. Smit, Sergio A. Lira, and Rob Leurs Copyright Ó 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32118-6 j3 1 Structural Aspects of Chemokines and their Interactions with Receptors and Glycosaminoglycans Amanda E. I. Proudfoot, India Severin, Damon Hamel, and Tracy M. Handel 1.1 Introduction Chemokines are a large subfamily of cytokines (50 in humans) that can be distinguished from other cytokines due to several features. They share a common biological activity, which is the control of the directional migration of leukocytes, hence their name, chemoattractant cytokines. They are all small proteins (approx. 8 kDa) that are highly basic, with two exceptions (MIP-1a, MIP-1b). Also, they have a highly conserved monomeric fold, constrained by 1–3 disulfides which are formed from a conserved pattern of cysteine residues (the majority of chemokines have four cysteines). The pattern of cysteine residues is used as the basis of their division into subclasses and for their nomenclature. The first class, referred to as CXC or a-chemokines, have a single residue between the first N-terminal Cys residues, whereas in the CC class, or b-chemokines, these two Cys residues are adjacent. While most chemokines have two disulfides, the CC subclass also has three members that contain three. Subsequent to the CC and CXC families, two fi additional subclasses were identi ed, the CX3C subclass [1, 2], which has three amino acids separating the N-terminal Cys pair, and the C subclass, which has a single disulfide. -
Yabe R Et Al, 2014.Pdf
International Immunology, Vol. 27, No. 4, pp. 169–181 © The Japanese Society for Immunology. 2014. All rights reserved. doi:10.1093/intimm/dxu098 For permissions, please e-mail: [email protected] Advance Access publication 25 October 2014 CCR8 regulates contact hypersensitivity by restricting cutaneous dendritic cell migration to the draining lymph nodes Rikio Yabe1,2,3,*, Kenji Shimizu1,2,*, Soichiro Shimizu2, Satoe Azechi2, Byung-Il Choi2, Katsuko Sudo2, Sachiko Kubo1,2, Susumu Nakae2, Harumichi Ishigame2, Shigeru Kakuta4 and Yoichiro Iwakura1,2,3,5 1Center for Animal Disease Models, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science, Noda, Chiba 278-0022, Japan 2Center for Experimental Medicine and Systems Biology, The Institute of Medical Science, University of Tokyo (IMSUT), Minato-ku, Tokyo 108-8639, Japan 3Medical Mycology Research Center, Chiba University, Inohana Chuo-ku, Chiba 260-8673, Japan RTICLE 4 A Department of Biomedical Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, FEATURED Tokyo 113-8657, Japan 5Core Research for Evolutional and Technology (CREST), Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan Correspondence to: Y. Iwakura; E-mail: [email protected] *These authors equally contributed to this work. Received 2 September 2014, accepted 17 October 2014 Abstract Allergic contact dermatitis (ACD) is a typical occupational disease in industrialized countries. Although various cytokines and chemokines are suggested to be involved in the pathogenesis of ACD, the roles of these molecules remain to be elucidated. CC chemokine receptor 8 (CCR8) is one such molecule, of which expression is up-regulated in inflammatory sites of ACD patients. -
Plasma Macrophage-Derived Chemokine (CCL22) and Its
Egypt J Pediatr Allergy Immunol 2005; 3(1): 20-31. Original article Plasma macrophage-derived chemokine (CCL22) and its receptor CCR4 on peripheral blood T lymphocytes of asthmatic children Background: The macrophage-derived chemokine (MDC/CCL22) acts on Mohamed H. Ezzat, CC chemokine receptor-4 (CCR4) to direct trafficking and recruitment of T Karim Y. Shaheen*. helper-2 (TH2) cells into sites of allergic inflammation. It was previously found overexpressed in lesional samples from adult asthmatics. Objective: This study is aimed to investigate the participation of CCR4/MDC axis in the development of TH2-dominated allergen-induced From the Departments childhood asthma in relation to disease activity, attack severity, and of Pediatrics and response to therapy, and to outline its value in differentiating atopic asthma Clinical Pathology*, from infection-associated airway reactivity. Faculty of Medicine, Methods: Proportion of CCR4-expressing peripheral blood T lymphocytes Ain Shams University, + (CCR4 PBTL%) were purified and quantitated by negative selection from Cairo, Egypt. peripheral blood mononuclear cells by flow cytometry, and the concentration of MDC in plasma was measured by ELISA in 32 children with atopic asthma (during exacerbation and remission), as well as in 12 children with acute lower respiratory tract infections (ALRTI), and 20 healthy children serving as controls. Results: The mean plasma MDC level (925±471.5 pg/ml) and CCR4+PBTL% (55.3±23.6%) were significantly higher in asthmatic children during acute attacks in comparison to children with ALRTI (109±27.3 pg/ml and 27.6±7.5%) and healthy controls (99.6±25.6 pg/ml and 24.2±4.1%). -
High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils
High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. M Uguccioni, … , M Baggiolini, C A Dahinden J Clin Invest. 1997;100(5):1137-1143. https://doi.org/10.1172/JCI119624. Research Article Eosinophil leukocytes express high numbers of the chemokine receptor CCR3 which binds eotaxin, monocyte chemotactic protein (MCP)-4, and some other CC chemokines. In this paper we show that CCR3 is also highly expressed on human blood basophils, as indicated by Northern blotting and flow cytometry, and mediates mainly chemotaxis. Eotaxin and MCP-4 elicited basophil migration in vitro with similar efficacy as regulated upon activation normal T cells expressed and secreted (RANTES) and MCP-3. They also induced the release of histamine and leukotrienes in IL-3- primed basophils, but their efficacy was lower than that of MCP-1 and MCP-3, which were the most potent stimuli of exocytosis. Pretreatment of the basophils with a CCR3-blocking antibody abrogated the migration induced by eotaxin, RANTES, and by low to optimal concentrations of MCP-4, but decreased only minimally the response to MCP-3. The CCR3-blocking antibody also affected exocytosis: it abrogated histamine and leukotriene release induced by eotaxin, and partially inhibited the response to RANTES and MCP-4. In contrast, the antibody did not affect the responses induced by MCP-1, MCP-3, and macrophage inflammatory protein-1alpha, which may depend on CCR1 and CCR2, two additional receptors detected by Northern blotting with basophil RNA. This study demonstrates that CCR3 is the major receptor for eotaxin, RANTES, and MCP-4 in human basophils, and suggests that basophils and eosinophils, which are the characteristic […] Find the latest version: https://jci.me/119624/pdf High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils Role in Activation by Eotaxin, MCP-4, and Other Chemokines Mariagrazia Uguccioni,* Charles R. -
Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
cancers Review Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them? Justine Cinier 1,†, Margaux Hubert 1,†, Laurie Besson 1, Anthony Di Roio 1 ,Céline Rodriguez 1, Vincent Lombardi 2, Christophe Caux 1,‡ and Christine Ménétrier-Caux 1,*,‡ 1 University of Lyon, Claude Bernard Lyon 1 University, INSERM U-1052, CNRS 5286 Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; [email protected] (J.C.); [email protected] (M.H.); [email protected] (L.B.); [email protected] (A.D.R.); [email protected] (C.R.); [email protected] (C.C.) 2 Institut de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France; [email protected] * Correspondence: [email protected] † Co-first authorship. ‡ Co-last authorship. Simple Summary: The immune response against cancer is generated by effector T cells, among them cytotoxic CD8+ T cells that destroy cancer cells and helper CD4+ T cells that mediate and support the immune response. This antitumor function of T cells is tightly regulated by a particular subset of CD4+ T cells, named regulatory T cells (Tregs), through different mechanisms. Even if the complete inhibition of Tregs would be extremely harmful due to their tolerogenic role in impeding autoimmune diseases in the periphery, the targeted blockade of their accumulation at tumor sites or their targeted Citation: Cinier, J.; Hubert, M.; depletion represent a major therapeutic challenge. This review focuses on the mechanisms favoring Besson, L.; Di Roio, A.; Rodriguez, C.; Treg recruitment, expansion and stabilization in the tumor microenvironment and the therapeutic Lombardi, V.; Caux, C.; strategies developed to block these mechanisms. -
Anti-Γδ TCR Antibody-Expanded Γδ T Cells
Cellular & Molecular Immunology (2012) 9, 34–44 ß 2012 CSI and USTC. All rights reserved 1672-7681/12 $32.00 www.nature.com/cmi RESEARCH ARTICLE Anti-cd TCR antibody-expanded cd T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies Jianhua Zhou, Ning Kang, Lianxian Cui, Denian Ba and Wei He Cell-based immunotherapy for lymphoid malignancies has gained increasing attention as patients develop resistance to conventional treatments. cd T cells, which have major histocompatibility complex (MHC)-unrestricted lytic activity, have become a promising candidate population for adoptive cell transfer therapy. We previously established a stable condition for expanding cd T cells by using anti-cd T-cell receptor (TCR) antibody. In this study, we found that adoptive transfer of the expanded cd T cells to Daudi lymphoma-bearing nude mice significantly prolonged the survival time of the mice and improved their living status. We further investigated the characteristics of these antibody-expanded cd T cells compared to the more commonly used phosphoantigen-expanded cd T cells and evaluated the feasibility of employing them in the treatment of lymphoid malignancies. Slow but sustained proliferation of human peripheral blood cd T cells was observed upon stimulation with anti-cd TCR antibody. Compared to phosphoantigen-stimulated cd T cells, the antibody-expanded cells manifested similar functional phenotypes and cytotoxic activity towards lymphoma cell lines. It is noteworthy that the anti-cd TCR antibody could expand both the Vd1 and Vd2 subsets of cd T cells. The in vitro-expanded Vd1 T cells displayed comparable tumour cell-killing activity to Vd2 T cells. -
Mice Chemokine Receptors CCR2 and CCR5 in Expression and Characterization Of
Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice This information is current as Matthias Mack, Josef Cihak, Christopher Simonis, Bruno of September 28, 2021. Luckow, Amanda E. I. Proudfoot, Jir?í Plachý, Hilke Brühl, Michael Frink, Hans-Joachim Anders, Volker Vielhauer, Jochen Pfirstinger, Manfred Stangassinger and Detlef Schlöndorff J Immunol 2001; 166:4697-4704; ; Downloaded from doi: 10.4049/jimmunol.166.7.4697 http://www.jimmunol.org/content/166/7/4697 References This article cites 40 articles, 27 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/166/7/4697.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice1 Matthias Mack,2* Josef Cihak,† Christopher Simonis,* Bruno Luckow,* Amanda E. I.